查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853617

臍帶血處理產品市場按產品類型、應用、最終用戶、處理方法、服務供應商和樣本類型分類－全球預測，2025-2032年

Umbilical Cord Blood Processing Products Market by Product Type, Application, End User, Processing Method, Service Provider, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，臍帶血處理產品市場規模將成長 39.8 億美元，複合年成長率為 11.27%。

關鍵市場統計數據
基準年 2024 16.9億美元
預計年份：2025年 18.9億美元
預測年份 2032 39.8億美元
複合年成長率 (%) 11.27%

隨著臨床創新、品質要求和業務重點的演變，制定臍帶血處理產品的策略背景

本導言旨在為快速發展的臍帶血處理產品領域提供背景資訊，該領域融合了臨床創新、監管演變和營運現代化。細胞療法和再生醫學的進步凸顯了精準、高效且無菌的處理方案的重要性，迫使臨床、研究和商業相關人員重新思考從採集到儲存的整個工作流程。同時，該行業在品管、可追溯性和可擴展性方面也面臨日益嚴格的審查，促使各機構重新審視傳統的手工操作方法，並選擇能夠確保可重複性並降低污染風險的技術。

在此背景下，本報告概述了影響策略選擇的關鍵主題促進因素：將自動化系統整合到現有實驗室基礎設施中；區分封閉式和開放式系統結構；以及在可自訂的手動套件通訊協定和優先考慮速度和合規性的預包裝套件之間進行權衡。報告還提供了一個視角，用於評估最終用戶（生物技術公司、醫院和診所以及研究機構）的需求，每個用戶在治療產品線、臨床吞吐量和臨床實驗活動方面都有不同的優先事項。有了這個基礎概述，主管們就可以以務實的視角解讀後續分析，重點在於營運準備、監管合規性以及跨部門合作的潛力。

技術自動化、通訊協定靈活性和治療進展如何推動混合策略並重塑臨床和研究環境中的處理工作流程

技術、工作流程設計和政策的變革性轉變正在重新定義人們對臍帶血處理解決方案的期望。自動化不再是小眾的增強功能，而是對可重複性、勞動力利用率和污染控制有直接影響的策略性槓桿。旨在最大限度減少操作人員干預並維持無菌屏障的封閉式自動化系統，越來越受到尋求更高通量和更穩定結果的臨床實驗室的青睞。相較之下，開放式系統保留了客製化方案和流程調整的靈活性，使其非常適合方法客製化至關重要的研究環境和小型臨床機構。

手動試劑套件將繼續發揮補充作用，尤其是在方案需要適應性或資金投入限制導致自動化普及延遲的情況下。可自訂的手動方案能夠針對特定應用進行流程客製化，而成套套件提供簡化的工作流程，有助於合規性和操作人員培訓。同時，應用層級的轉變，例如CAR-T療法的成熟和再生醫學技術的擴展，凸顯了對能夠維持細胞活力和功能特性的處理方法的需求。這些轉變的整合將迫使各機構採用混合策略，以平衡自動化系統的嚴謹性和擴充性與手動試劑套件的適應性和低初始成本，從而滿足臨床和臨床實驗的雙重需求。

透過調整供應商策略、在地化措施和庫存管理，應對關稅主導的採購壓力，並保障產品品質和供應。

美國關稅的實施為臍帶血加工產品相關企業的籌資策略、供應鏈配置和成本管理帶來了複雜的影響。關稅對進口零件和整套系統的影響各不相同，這將改變供應商的選擇考量，促使買家尋求供應商多元化、探索近岸外包方案並重新評估庫存策略。對於依賴全球供應鏈取得專用零件（例如無菌一次性組件、離心機試劑組）的製造商而言，關稅帶來的成本壓力可能會加速其尋找替代供應商或重新設計以降低關稅風險的進程。

為因應此局面，一些機構可能會採取策略性儲備關鍵耗材或重新談判長期合約以穩定單位成本。另一些機構則可能採取在地化策略，例如與國內委託製造合作或投資區域組裝能力，以降低關稅風險，同時保持技術專長。關稅環境也將影響與終端用戶的價格談判，尤其是預算有限的醫院和研究機構。最終，關稅將成為營運彈性規劃的催化劑，促使採購、合規和產品開發團隊之間加強合作，以控制總體擁有成本，同時確保加工耗材和系統的品質和可用性。

對產品架構、治療用途、最終用戶畫像、加工技術、服務模式和樣品所有權框架進行全面的細分映射

透過細緻的細分視角，我們揭示了不同產品類型、應用、最終用戶、處理方法、服務供應商和樣本所有權模式下的差異化需求促進因素和採購行為。基於產品類型的分析區分了自動化系統和手動套件，其中自動化系統進一步細分為封閉式系統和開放式系統；手動試劑套件則區分了可自訂通訊協定和預包裝套件。按應用領域分類，我們探討了免疫療法、再生醫學和移植領域。免疫療法包括CAR-T療法和NK細胞擴增，再生醫學包括組織工程和創傷治療，移植領域包括造血幹細胞和間質幹細胞的應用。這種應用層面的細分清晰地表明，處理精確度和細胞完整性是至關重要的。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用臍帶血進行細胞治療和再生醫學的需求日益成長
  • 創新自動化處理技術，最大限度地提高臍帶血幹細胞產量
  • 整合人工智慧和機器學習技術，以提高臍帶血處理後的品管和活力評估。
  • 擴大生技公司與臍帶血庫之間的合作，以擴大儲存和分發網路
  • 新興的公私合營模式旨在提高臍帶血庫服務的可及性
  • 各大市場正逐步改善監管法規，以實現統一的處理標準和認證要求。
  • 開發用於現場臍帶血採集和處理的可攜式即時檢驗（POC）處理設備
  • 提高封閉式處理套件的使用率，以最大限度地減少污染並提高臍帶血單位的臨床效用
  • 體外幹細胞擴增技術的進步提高了單份臍帶血單位的治療細胞劑量
  • 在資源匱乏的環境中，採取節省成本的策略來推進臍帶血微處理解決方案。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8.臍帶血處理產品市場（依產品類型分類）

  • 自動化系統
    • 封閉式系統
    • 開放系統
  • 手冊套件
    • 可自訂通訊協定
    • 預包裝套件

9. 按應用分類的臍帶血處理產品市場

  • 免疫療法
    • CAR-T療法
    • NK細胞增殖
  • 再生醫學
    • 組織工程
    • 創傷治療
  • 移植
    • 造血幹細胞
    • 間質幹細胞

第10章 依最終用戶分類的臍帶血處理產品市場

  • 生技公司
    • 大型製藥公司
    • 小型企業
  • 醫院和診所
    • 大學醫院
    • 社區醫院
  • 研究所
    • CRO
    • 大學

第11章 依加工方法分類的臍帶血加工產品市場

  • 細胞分離
    • CD34 選擇
    • 紅血球清除
  • 體積減少
    • 離心
    • 過濾

第12章 臍帶血處理產品市場（依服務供應商分類）

  • 合約服務
    • CRO
    • TPL
  • 內部

第13章 依樣本類型分類的臍帶血處理產品市場

  • 私人銀行
    • 自體血庫
    • 家庭銀行
  • 大眾銀行

第14章 臍帶血處理產品市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 臍帶血處理產品市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國臍帶血處理產品市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Cord Blood Registry, LLC
    • Cryo-Cell International, Inc.
    • ViaCord, LLC
    • Americord Registry LLC
    • China Cord Blood Corporation
    • Vita 34 AG
    • StemCyte, Inc.
    • LifeCell International Pvt. Ltd.
    • Cordlife Group Limited
    • Cord Blood America, Inc.
Product Code: MRR-6849E8ED80B7

The Umbilical Cord Blood Processing Products Market is projected to grow by USD 3.98 billion at a CAGR of 11.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.69 billion
Estimated Year [2025] USD 1.89 billion
Forecast Year [2032] USD 3.98 billion
CAGR (%) 11.27%

Framing the strategic context for umbilical cord blood processing products amid clinical innovation, quality demands, and evolving operational priorities

The introduction establishes the context for a rapidly evolving domain where umbilical cord blood processing products intersect clinical innovation, regulatory evolution, and operational modernization. Advances in cell-based therapies and regenerative medicine have elevated the importance of precise, efficient, and sterility-assured processing solutions, prompting stakeholders across clinical, research, and commercial settings to reassess workflows from collection to storage. Simultaneously, the industry faces intensified scrutiny around quality controls, traceability, and scalability, leading organizations to reconsider traditional manual approaches in favor of technologies that promise reproducibility and reduced contamination risk.

Against this backdrop, the report frames key thematic drivers shaping strategic choices: integration of automated systems within existing laboratory infrastructures; differentiation between closed and open-system architectures; and the trade-offs between customizable manual kit protocols and prepackaged kits that prioritize speed and compliance. It also establishes a lens for evaluating end-user needs spanning biotechnology companies, hospitals and clinics, and research institutions, each with distinct priorities linked to therapeutic pipelines, clinical throughput, and investigational activity. This foundational overview prepares executives to interpret subsequent analysis through a pragmatic lens that emphasizes operational readiness, regulatory alignment, and the potential for cross-sector collaboration.

How technological automation, protocol flexibility, and therapeutic advances are driving hybrid strategies and reshaping processing workflows across clinical and research settings

Transformative shifts across technology, workflow design, and policy are redefining expectations for cord blood processing solutions. Automation is no longer a niche enhancement but a strategic lever that directly affects reproducibility, labor utilization, and contamination control. Closed automated systems, designed to minimize operator intervention and maintain aseptic barriers, are increasingly attractive to clinical laboratories pursuing higher throughput and consistent outcomes. By contrast, open systems retain flexibility for bespoke protocols and process adjustments, keeping them relevant for research settings and small-scale clinical operations where method customization is essential.

Manual kits continue to play a complementary role, particularly where protocols demand adaptability or where capital expenditure constraints delay automation adoption. Customizable manual protocols enable process tailoring for niche applications, while prepackaged kits deliver simplified workflows that aid compliance and operator training. Concurrently, application-level shifts such as the maturation of CAR-T therapies and expanding regenerative medicine techniques emphasize the need for processing methods that preserve cell viability and functional characteristics. These converging shifts compel organizations to adopt hybrid strategies that balance the rigor and scalability of automated systems with the adaptability and lower initial costs of manual kits, thereby positioning them to respond to both clinical and investigational demands.

Navigating tariff-driven procurement pressures by recalibrating supplier strategies, localization efforts, and inventory practices to protect quality and availability

The imposition of tariffs in the United States introduces a complex overlay to procurement strategies, supply chain configurations, and cost management for firms involved in cord blood processing products. Tariff measures affect imported components and complete systems differently, altering vendor selection calculus and encouraging buyers to reassess supplier diversification, nearshoring options, and inventory policies. For manufacturers that rely on global supply chains for specialized components such as sterile single-use assemblies, centrifuge rotors, or reagent kits, tariff-related cost pressures may accelerate efforts to qualify alternative suppliers or to reconfigure designs to reduce tariff exposure.

In response, some organizations are likely to adopt strategic stockpiling of critical consumables or to renegotiate long-term contracts to stabilize unit costs. Others may pursue localization strategies, including partnerships with domestic contract manufacturers or investments in regional assembly capabilities that mitigate tariff risk while preserving access to technological expertise. The tariff environment also affects pricing negotiations with end users, particularly for hospitals and research institutions operating under constrained budgets. Ultimately, tariffs act as a catalyst for operational resilience planning, driving a closer alignment between procurement, regulatory compliance, and product development teams to manage total cost of ownership while maintaining quality and availability of processing supplies and systems.

Comprehensive segmentation mapping across product architectures, therapeutic uses, end-user profiles, processing techniques, service models, and sample ownership frameworks

A nuanced segmentation view reveals differentiated demand drivers and procurement behaviors across product types, applications, end users, processing methods, service providers, and sample ownership models. Based on product type, analysis distinguishes between Automated Systems and Manual Kits, with Automated Systems further categorized into Closed Systems and Open Systems, and Manual Kits differentiated into Customizable Protocols and Prepackaged Kits; these distinctions illuminate trade-offs between throughput, sterility assurance, and protocol flexibility. Based on application, the landscape is examined across Immunotherapy, Regenerative Medicine, and Transplantation, where Immunotherapy includes CAR-T Therapy and NK Cell Expansion, Regenerative Medicine covers Tissue Engineering and Wound Healing, and Transplantation encompasses Hematopoietic Stem Cell and Mesenchymal Stem Cell uses; this application-level breakdown clarifies where processing fidelity and cell integrity are most mission-critical.

Based on end user, the market comprises Biotechnology Companies, Hospitals And Clinics, and Research Institutions, with Biotechnology Companies subdivided into Large Pharma and SMEs, Hospitals And Clinics split into Academic Hospitals and Community Hospitals, and Research Institutions incorporating Contract Research Organizations and Universities; these end-user definitions help explain procurement cycles, regulatory expectations, and adoption velocity. Based on processing method, analysis identifies Cell Separation and Volume Reduction, with Cell Separation including CD34 Selection and Red Cell Depletion, and Volume Reduction differentiating Centrifugation and Filtration; understanding these methodological choices is essential for evaluating equipment and consumable compatibility. Based on service provider, distinctions between Contract Services and In-House operations highlight the roles of Contract Research Organizations and Third-Party Laboratories in scaling specialized processing, while based on sample type, the market differentiates Private Banks and Public Banks, with Private Banks further classified into Autologous Banks and Family Banks; this ownership segmentation affects quality standards, custodial responsibilities, and commercial models. Together, these intersecting dimensions provide a comprehensive lens to align product design, regulatory compliance, and go-to-market approaches with distinct customer needs.

How regional regulatory regimes, clinical priorities, and banking models shape procurement choices and vendor strategies across major global markets

Regional dynamics exert a powerful influence on procurement preferences, regulatory requirements, and collaborative ecosystems. In the Americas, a concentration of advanced therapeutic development, active clinical trial networks, and a mature private banking sector favors early adoption of automated and closed systems that support regulated clinical workflows and large-scale processing demands. Transitioning from this regional profile, Europe, Middle East & Africa presents a heterogeneous mix of markets where regulatory harmonization and public bank infrastructures in some countries coexist with rapidly growing private banking interest in others; this environment encourages modular solutions that can be adapted to varied compliance regimes and resource constraints. Meanwhile, Asia-Pacific exhibits a blend of high-volume clinical populations, expanding biotech investment, and governmental initiatives that support regenerative medicine research, all of which create demand for both high-throughput automated platforms and accessible manual kits suited to decentralized facilities.

Across regions, differences in reimbursement frameworks, clinical trial regulatory pathways, and the prevalence of public versus private cord blood banks shape procurement and deployment timelines. For instance, regions with robust public bank networks may prioritize processing methods that optimize cell yield for transplantation, while markets with accelerating immunotherapy pipelines prioritize technologies that preserve functional cell characteristics relevant to ex vivo expansion. These regional nuances encourage vendors and service providers to pursue differentiated market entry strategies, collaborate with local laboratories and academic centers for validation studies, and design service offerings that reflect regional expectations for quality assurance, traceability, and customer support.

Company-level differentiation driven by integrated system-consumable design, service expansion, supply resilience, and strategic validation partnerships

Key company-level dynamics center on innovation in system design, consumable affordability, service breadth, and strategic partnerships that bridge clinical and research needs. Leading organizations differentiate themselves through integrated offerings that combine hardware platforms, single-use consumables, and validated workflows to reduce adoption friction and ensure reproducible outcomes. Strategic collaborations between system manufacturers and contract laboratories or academic centers accelerate validation across varied use cases and provide third-party evidence of performance under real-world conditions. Meanwhile, companies that expand service portfolios to include contract processing, method validation, and training services create sticky relationships with end users who prioritize turnkey solutions.

Operational excellence in manufacturing, supply chain resilience, and regulatory support are decisive competitive levers. Firms that invest in scalable production capacity for sterile disposables and that maintain multiple qualified suppliers for critical components mitigate disruption risks and protect customer continuity. At the same time, commercial strategies that address differentiated buyer segments-such as offering compact, cost-efficient kits for community hospitals and modular automated platforms for large research centers-enhance market reach. Finally, intellectual property around cell selection technologies, closed-system interfaces, and assay-compatible consumables can provide defensible differentiation, while transparent quality management and third-party certifications reinforce trust among clinical and research customers.

Actionable strategic steps for executives to balance automation scale, supply resilience, validation transparency, and service-led adoption pathways

Industry leaders should adopt a pragmatic mix of strategic investments and tactical adjustments to capture value in a complex, evolving landscape. First, prioritize modular automation that allows incremental deployment: organizations can phase in closed-system modules for high-volume workflows while retaining open-system capabilities for prototyping and method development. This approach preserves flexibility and manages capital intensity. Second, develop dual sourcing and regional supplier qualification programs to reduce tariff exposure and supply chain vulnerability, and couple those programs with contingency inventory policies that balance working capital with availability of critical consumables.

Third, invest in rigorous validation studies and publish technical performance data to shorten procurement cycles and build trust among hospital procurement teams and research institutions. Fourth, expand service portfolios to include method transfer support, training, and contract processing options that lower adoption barriers and create recurring revenue streams. Fifth, align product roadmaps with application-specific requirements-such as protocols optimized for CAR-T manufacturing or for mesenchymal stem cell preservation-ensuring that design choices reflect the sensitivity of target cell populations. Finally, cultivate strategic partnerships with banks, academic centers, and biotechnology companies to co-develop workflows and to secure early adopters for new platform releases, thereby accelerating field validation and commercial traction.

Methodological framework combining multi-stakeholder primary research, technical validation, and cross-checked analytical procedures to ensure robust insights

The research methodology combines a multi-source evidence base with rigorous validation steps to ensure analytical integrity and operational relevance. Primary research included structured consultations with stakeholders across vendors, hospital laboratories, research institutions, and contract service providers to capture experiential insights into procurement drivers, technology selection criteria, and operational pain points. These qualitative inputs were triangulated with technical specifications, regulatory documentation, and validation reports to assess product capabilities, workflow compatibility, and quality systems. In parallel, secondary research synthesized publicly available literature, patents, and clinical trial registries to map application trends and technological trajectories.

Analytical procedures emphasized cross-validation and scenario analysis. For example, technology capability assessments were reviewed against third-party validation studies and user-reported performance data to reconcile controlled-lab claims with real-world performance. Segmentation constructs were stress-tested through interviews with representative end users to ensure that categories-spanning product type, application, end user, processing method, service provider, and sample type-reflect practical decision-making frames. Finally, sensitivity checks and expert review panels were used to surface divergent viewpoints and to refine interpretations, ensuring that conclusions are grounded in a balanced appraisal of technological potential, operational constraints, and regulatory context.

Strategic synthesis emphasizing flexibility, validation, supply resilience, and collaboration as the foundation for sustained adoption and clinical impact

In conclusion, the domain of umbilical cord blood processing products is at an inflection point defined by the interplay of automation, therapeutic innovation, and supply chain realignment. Organizations that adopt flexible strategies-combining the reproducibility and contamination control benefits of closed automated systems with the adaptability and cost advantages of manual kits-will be better positioned to meet diverse user needs across clinical and research settings. Regional and tariff-driven dynamics require deliberate supply chain planning and localized partnership models to maintain continuity and control total cost exposure. Moreover, companies that invest in transparent validation, integrated service offerings, and targeted product roadmaps aligned with specific applications such as immunotherapy and transplantation will create durable value for customers.

Looking forward, the most resilient players will be those that incorporate iterative learning into product development, maintain diversified sourcing, and actively collaborate with clinical and academic partners to validate performance in situ. By emphasizing operational readiness, regulatory alignment, and customer-centric services, stakeholders can convert technical capabilities into sustained adoption and improved patient and research outcomes. This concluding synthesis underscores the importance of strategic adaptability as the cornerstone of long-term success in a rapidly evolving field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for cell therapy and regenerative medicine applications using cord blood
  • 5.2. Innovations in automated processing technologies that maximize stem cell yield from umbilical cord blood
  • 5.3. Integration of artificial intelligence and machine learning to improve quality control and viability assessment of processed cord blood
  • 5.4. Increasing partnerships between biotechnology firms and cord blood banks to expand storage and distribution networks
  • 5.5. Emergence of private public collaborative models to enhance accessibility of cord blood banking services
  • 5.6. Regulatory evolution toward harmonized processing standards and accreditation requirements across key markets
  • 5.7. Development of portable point of care processing devices for on site umbilical cord blood collection and handling
  • 5.8. Growing adoption of closed system processing kits to minimize contamination and improve clinical usability of cord blood units
  • 5.9. Advances in ex vivo stem cell expansion techniques to increase therapeutic cell doses from single cord blood units
  • 5.10. Cost reduction strategies driving microvolume processing solutions for umbilical cord blood in resource limited settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Umbilical Cord Blood Processing Products Market, by Product Type

  • 8.1. Automated Systems
    • 8.1.1. Closed Systems
    • 8.1.2. Open Systems
  • 8.2. Manual Kits
    • 8.2.1. Customizable Protocols
    • 8.2.2. Prepackaged Kits

9. Umbilical Cord Blood Processing Products Market, by Application

  • 9.1. Immunotherapy
    • 9.1.1. CAR-T Therapy
    • 9.1.2. NK Cell Expansion
  • 9.2. Regenerative Medicine
    • 9.2.1. Tissue Engineering
    • 9.2.2. Wound Healing
  • 9.3. Transplantation
    • 9.3.1. Hematopoietic Stem Cell
    • 9.3.2. Mesenchymal Stem Cell

10. Umbilical Cord Blood Processing Products Market, by End User

  • 10.1. Biotechnology Companies
    • 10.1.1. Large Pharma
    • 10.1.2. SMEs
  • 10.2. Hospitals And Clinics
    • 10.2.1. Academic Hospitals
    • 10.2.2. Community Hospitals
  • 10.3. Research Institutions
    • 10.3.1. Contract Research Organizations
    • 10.3.2. Universities

11. Umbilical Cord Blood Processing Products Market, by Processing Method

  • 11.1. Cell Separation
    • 11.1.1. CD34 Selection
    • 11.1.2. Red Cell Depletion
  • 11.2. Volume Reduction
    • 11.2.1. Centrifugation
    • 11.2.2. Filtration

12. Umbilical Cord Blood Processing Products Market, by Service Provider

  • 12.1. Contract Services
    • 12.1.1. Contract Research Organizations
    • 12.1.2. Third-Party Laboratories
  • 12.2. In-House

13. Umbilical Cord Blood Processing Products Market, by Sample Type

  • 13.1. Private Banks
    • 13.1.1. Autologous Banks
    • 13.1.2. Family Banks
  • 13.2. Public Banks

14. Umbilical Cord Blood Processing Products Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Umbilical Cord Blood Processing Products Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Umbilical Cord Blood Processing Products Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Cord Blood Registry, LLC
    • 17.3.2. Cryo-Cell International, Inc.
    • 17.3.3. ViaCord, LLC
    • 17.3.4. Americord Registry LLC
    • 17.3.5. China Cord Blood Corporation
    • 17.3.6. Vita 34 AG
    • 17.3.7. StemCyte, Inc.
    • 17.3.8. LifeCell International Pvt. Ltd.
    • 17.3.9. Cordlife Group Limited
    • 17.3.10. Cord Blood America, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL UMBILICAL CORD BLOOD PROCES